Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman


The bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that Jean Stéphenne has been appointed Chairman of the Board of Directors with immediate effect, replacing Steve Swinson who has informed the Board of his intention to step down.

Jean Stéphenne is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix. Together with the Board of TiGenix, he oversaw the clinical development and market approval of its most advanced allogeneic cell therapy product for the treatment of complex perianal fistulas in Crohn’s disease, resulting in Takeda’s announced intention to acquire the company for EUR 520 million.

Jean Stéphenne was also previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees.

Jean Stéphenne currently serves on the Board of various life sciences companies including TiGenix, Vaxxilon, OncoDNA, CureVac and Bepharbel. Previous board positions include Besix Group, BNP Paribas Fortis, GBL and IBA. For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honoured with various titles by the Belgian and British governments


Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: “We are delighted to welcome Jean Stéphenne as our new Chairman of the Board. Jean Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector. We are pleased to have attracted a Chairman of such calibre, a testament to the potential of our unique bone cell therapy platform. Jean Stéphenne will be a valuable addition to an already strong Board, as we advance our allogeneic cell therapy platform through critical clinical studies and towards commercialization. I would also like to express my thanks, on behalf of the Board and leadership team, to Steve Swinson, who has provided valuable strategic counsel during his time with the Company.”


Jean Stéphenne, Chairman of Bone Therapeutics commented: “Bone Therapeutics is a highly innovative Company at the forefront of developments in bone cell therapy and I am very excited to be joining the Board. I look forward to working closely with Thomas, the rest of the Board and the whole Bone Therapeutics team as we move towards important value inflection points for the Company’s bone cell therapy products for the benefit of patients.”


Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

Our primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip, and is also partnered with Asahi Kasei Corporation for the development and commercialisation of PREOB® in Japan.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?